MétaCan
Menu
Back to cohort
Record W2998006477 · doi:10.14245/ns.19edi.018

Acidic Fibroblast Growth Factor in Spinal Cord Injury: A Potential Therapy Which Merits Further Investigation

2019· editorial· en· W2998006477 on OpenAlexaff
Kazuya Yokota, Michael G. Fehlings

Bibliographic record

VenueNeurospine · 2019
Typeeditorial
Languageen
FieldMedicine
TopicSpinal Cord Injury Research
Canadian institutionsToronto Western HospitalUniversity of TorontoUniversity Health Network
Fundersnot available
KeywordsSpinal cord injuryFibroblast growth factorSpinal cordMedicineNeurosciencePsychologyInternal medicine

Abstract

fetched live from OpenAlex

In the current issue of Neurospine, Ko et al. 1 reviewed the traumatic spinal cord injury (SCI) clinical trials completed this decade; focusing on the application of acidic fibroblast growth factor (aFGF) to promote neural regeneration.FGFs are a family of growth factors that are involved in angiogenesis, wound healing, embryonic development, and various endocrine signaling pathways.2 When applied in the setting of SCI, FGF attenuates biological processes that are associated with secondary injury such as astrocyte activation, neuroinflammation, and scar formation.3 These favorable attributes make aFGF a tempting therapeutic candidate for SCI.In a phase I study of aFGF, 9 patients with chronic cervical SCI were treated with aFGF in fibrin glue via a laminectomy, followed by booster aFGF administration at 3-and 6-month postinjury.Modest nerve regeneration occurred in all patients, and 2 patients showed improvement in American Spinal Cord Injury Association (ASIA) motor scores.4 This was followed by an open label, nonrandomized, uncontrolled phase II trial in 2011 that demonstrated significant improvement in ASIA motor and sensory scores, as well as increased functional independence measures 1 year after aFGF intervention.5 Furthermore, throughout the 4-year follow-up period of the clinical trial, the authors found that aFGF administration improved functional recovery without any clinically related major adverse events.6 The aforementioned clinical reports of aFGF are meaningful because they confirm the safety of aFGF administration, including the absence of any tumorigenic episodes within the injured spinal cord.However, the readers of the review article should be aware of a pitfall when interpreting the aFGF trials with regards to the timing of patient recruitment and intervention.Notably, the timing for initiation of aFGF administration was broad: from 2.3 to 105.4 months after injury in the cervical SCI group and from 1.5 to 135.8 months after injury in the thoracolumbar group.The recruited patients in the trial were subacute or chronic SCI patients described in the article as being in a 'relatively stable neurological status, ' which implies that the potential natural recovery during the follow-up period would be comparable among enrolled patients.The international campaign for cures of spinal cord injury paralysis (ICCP), which supports an international panel tasked with reviewing the methodology for clinical trials in SCI, states that spontaneous recovery can be observed in

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Editorial · Consensus signal: none
Teacher disagreement score0.005
Threshold uncertainty score0.016

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.003
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0010.001
Science and technology studies0.0010.001
Scholarly communication0.0020.003
Open science0.0010.001
Research integrity0.0050.006
Insufficient payload (model declined to judge)0.0050.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.033
GPT teacher head0.351
Teacher spread0.319 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreEditorial

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations6
Published2019
Admission routes1
Has abstractyes

Explore more

Same venueNeurospineSame topicSpinal Cord Injury ResearchFrench-language works237,207